• Home
  • Victims
    • Vaccine Victims Memorial
    • Gardasil & Silgard
      • G / S Australasia
        • G / S Australia
        • G / S New Zealand
      • G / S Europe
        • G / S Czech Republic
        • G / S Denmark
        • G / S France
        • G / S Germany
        • G / S Ireland
        • G / S Italy
        • G / S Norway
        • G / S Scotland
        • G / S Spain
        • G / S United Kingdom
      • G / S N. America
        • G / S Canada
        • G / S Mexico
        • G / S United States
      • G / S S. America
        • G / S Brazil
        • G/S Colombia
    • Cervarix
      • Cervarix Asia
        • Cervarix India
        • Cervarix Philippines
      • Cervarix Europe
        • Cervarix Czech
        • Cervarix Netherlands
        • Cervarix Scotland
        • Cervarix Slovakia
        • Cervarix Spain
        • Cervarix UK
      • Cervarix N. America
        • Cervarix Mexico
  • Resources
    • HPV Testing Resources
      • Pre-HPV Vaccination
      • Post-HPV Vaccination
    • Medical Professionals
    • Vaccine Injury Attorneys
    • Political Action Groups
    • Vaccine Groups
    • Vaccine Victims Hotline
  • SANE Vax Press Releases
  • Videos
    • Vaccine Safety Videos
    • Vaccine Victim Videos
    • Pharma Videos
  • About
    • About Us
    • Who We Are
    • Press Releases
    • SANE Vax in the News
    • Contact Us

SaneVax, Inc.

The First International HPV Vaccine Information Clearinghouse

  • NEWS
    • Government Agencies
      • African
      • Asian
      • Australasian
      • European
      • North American
      • South American
      • United Nations
      • WHO
    • Pharmaceutical Companies
      • CSL Biotherapies
      • GlaxoSmithKline
      • Inovio Pharmaceuticals
      • Liquidia Technologies
      • Merck & Co.
      • Novartis
      • Pfizer
      • Qiagen
      • Sanofi Aventis
      • Sanofi Pasteur MSD spmsd
      • Wyeth Laboratories
    • Science & Medicine
      • Cancer
      • Clinical Trials
      • Environmental Health
      • Heavy Metal Toxicity
      • HPV Science
      • Influenza
      • Meningitis
      • Pertussis
      • Pharmaceuticals
      • Rotavirus
      • STD’s
      • Vaccine Science
      • Women’s Health
    • Vaccine Adverse Events
    • Vaccine Injury Reporting
      • VAERS
      • VAMPSS
    • Vaccine Litigation
    • Vaccine Marketing
    • Vaccine Politics/People
    • Vaccine Victims
      • Cervarix Injuries
      • DTP/DTaP Injuries
      • Fluvax Injuries
      • Fluzone Injuries
      • Gardasil / Silgard Injuries
      • Menomune Injuries
      • MMR Injuries
      • Polio Vaccine Injuries
      • Synflorix Injuries
      • Yellow Fever Vaccine
    • Vaccines
      • Anthrax
      • Breast Cancer
      • Chicken Pox
      • Cholera
      • Combination Vaccines
      • Diphtheria
      • Hepatitis B
      • HPV
      • Influenza Vaccines
      • Malaria
      • Measles
      • Meningitis Vaccines
      • MRSA
      • Mumps
      • Norovirus
      • Pertussis Vaccines
      • Pneumococcal Disease
      • Polio
      • Rotavirus Vaccines
      • Shingles
      • Smallpox
      • TB
      • Tetanus
      • Typhoid
      • Yellow Fever Vaccine
    • Vaccines and the Media
  • WORLD NEWS
    • Africa
    • Asia
    • Australasia
    • Europe
    • North America
    • South America
  • RESEARCH
    • Cancer Research
    • Cervarix Vaccine
    • Gardasil/Silgard Vaccine
    • Human Pap. Research
    • Immunization Practices
    • Neurology
    • Vaccine Adjuvants
    • Vac. Ingredient Research
    • Vaccine Injuries
    • Vaccine Preservatives
    • Vaccine Related Research
    • Vaccine Safety
  • CITIZENS SPEAK
    • Cervical Cancer Debate
    • HPV Vax
      • Australian Concerns
      • Canadian Concerns
      • Irish Concerns
      • Spain Concerns
      • UK Concerns
      • United States Concerns
You are here: Home / NEWS . . . . . . . . / Vaccine Adverse Events / Endocrine System / Cervical Cancer HPV / T-cell response to human papillomavirus type 58 L1, E6 and E7 peptides in women with cleared infection, cervical intraepithelial neoplasia and invasive cancer

T-cell response to human papillomavirus type 58 L1, E6 and E7 peptides in women with cleared infection, cervical intraepithelial neoplasia and invasive cancer

August 7, 2010 By Jonathan Leave a Comment

PubMed.gov

Clin Vaccine Immunol. 2010 Jul 28. [Epub ahead of print]

Chan PK, Liu SJ, Cheung TH, Yeo W, Ngai SM, Cheung JL, Chong P, Man S.

Departments of Microbiology, Obstetrics and Gynaecology, Clinical Oncology and Biology, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, China; Vaccine Development and Research Center, National Health Research Institutes, Miaoli, Taiwan; Graduate Institute of Immunology, China Medical University, Taichung, Taiwan; Department of Infection, Immunity and Biochemistry, Cardiff University School of Medicine, Henry Wellcome Building, Heath Park, Cardiff, CF14 4XN, United Kingdom.

Abstract

Human papillomavirus (HPV) 58 exists in a relatively high prevalence in certain parts of the world including East Asia. This study examined T-cell response to HPV 58 L1, E6 and E7 peptides among women with cleared infection, cervical intraepithelial neoplasia (CIN) grade 2 and 3, and invasive cervical cancer (ICC). Peptides found reactive in the in-vitro peptide binding assay or mouse stimulating study were tested with interferon-gamma enzyme-linked immunospot (IFN-gamma ELISPOT) assay to detect peptide-specific response from the peripheral blood mononuclear cells (PBMC) collected from 91 HPV 58-infected women (32 with cleared infection, 16 CIN2, 15 CIN3, and 28 ICC). Four HLA A11-restricted HPV 58 L1 peptides located at amino acid positions 296-304, 327-335, 101-109 and 469-477 showed positive IFN-gamma ELISPOT results, and were mainly from women with cleared infection. Two HLA A11-restricted E6 peptides (amino acid positions 64-72 and 94-102), and three HLA A11-restricted E7 peptides (amino acid positions 78-86, 74-82, and 88-96) showed positive response. Response to E6 and E7 peptides was mainly observed from subjects with CIN2 or above. One HLA A2-restricted E6 peptide located at the amino acid position 99-107 had elicited positive response in two CIN2 subjects. One HLA A24-restricted L1 peptide located at amino acid position 468-476 also elicited positive response in two CIN2 subjects. In summary, this study has identified a few immunogenic epitopes for HPV 58 E6 and E7 proteins. It is worthwhile to further investigate whether response to these epitopes have a role in clearing an established cervical lesion.

Read Full Abstract…

Related

Filed Under: Cervical Cancer HPV Tagged With: Cervical Cancer HPV, HPV

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Follow Us

SaneVax on FacebookSaneVax on TwitterSaneVax on LinkedInSaneVax on YoutubeSaneVax RSS Feed

Help Support SaneVax

Notice: We need your support. This massive research & presentation comes from a team of volunteers. We need your help to keep this critical information available.



SaneVax relies on support from participants like you. We are a 501 (c)(3) non-profit corporation, donations are tax deductible. Help keep this venue available and support the spirit – Thank you!

This Week’s Survivor

Anna from Avila

Categories

Links

  • Creating an HPV Industry
  • File a VAERS Report
  • Gardasil and Unexplained Deaths
  • HPV Industry Timeline
  • HPV Mechanisms of Action in Women
  • HPV Vaccine Fact Sheet
  • Petition: Rescind HPV Vaccine Approval
  • Presentation to the FDA
  • Supreme Court Arguments

HPV Vaccine VAERS Reports

Description 12/14/2019  TOTAL
Disabled 3,092
Deaths 523
Did Not Recover 13,072
Abnormal Smear 695
Cervical Cancer 186
Infertility 52
Life-threatening 1,001
Emergency Room 15,419
Hospitalized 6,448
Extended Hosp. Stay 304
Serious 9,497
Total Adverse Events 64,270

Access expanded report here.

Related

Subscribe2


 

Log In

Featured Video

dangers

The Dangers of Vaccines – Part 1 (Autism MMR HPV Gardasil Swine Flu H1N1 Thimerosal)

News

SaneVax News Blog!
News

Videos

Safety • Victims • Pharma
No Genetic Epidemic

Contact

Contact S.A.N.E.Vax
S.A.N.E.VAX log thumbnail

Copyright © 2023 SaneVax, Inc. · Site by TheWebElves.com a div. of KalaRhythms.org · Log in